Anthem Biosciences

Anthem Biosciences’ initial public offering has garnered extraordinary interest from investors, with the issue subscribed an impressive 63 times by the close of bidding. This robust demand reflects market optimism surrounding the company’s growth trajectory, operational strengths, and the broader appeal of India’s thriving biopharmaceutical sector. Both institutional and retail investors raced to secure allocations, signaling confidence in Anthem’s business fundamentals and its potential to capitalize on global demand for specialized research and manufacturing services.

Anthem Biosciences’ initial public offering commenced on a measured note, garnering a subscription of 73% by the close of its opening day. While the offering drew steady interest from retail investors, institutional participation appeared cautious, reflecting broader market sentiments amid global economic uncertainties. The IPO, aimed at fueling the company’s expansion plans and reducing debt, has positioned Anthem as a notable contender in the contract research and manufacturing space.

Anthem Biosciences’ initial public offering has witnessed robust demand, achieving full subscription on the very first day of bidding. The Bengaluru-based contract research and manufacturing firm attracted considerable attention from institutional and retail investors alike, reflecting strong confidence in its business model and growth prospects. With a price band set between Rs. 463 and Rs. 480 per share, the IPO aims to raise Rs. 1,225 crore.

In a significant prelude to its highly anticipated initial public offering, Anthem Biosciences has secured Rs. 1,016 crore through anchor investor commitments. This substantial capital infusion highlights the strong appetite among institutional investors for opportunities in India’s fast-expanding contract research and manufacturing sector. Anthem’s move comes at a time when global pharmaceutical outsourcing demand is intensifying, placing the Bengaluru-based company in a favorable position to capitalize on industry tailwinds.